Abstract
This article presents an overview of legal, methodological, organisational, financial, structural and technical aspects of the initial audiological measurement of newborns (screening), follow-up (diagnosis) and tracking the results (tracking) within the German newborn hearing screening programme.
Highlights
Universal Newborn Hearing Screening (NHS), as defined in the Children’s Directive [1], has been part of the national programme for the screening of infants in Germany since 2009
Two automated methods for testing hearing in newborn hearing screening are permitted in Germany: automated auditory brainstem response audiometry (AABR) and automated measurement of transient-evoked otoacoustic emissions (ATEOAE) [1,6]
Parents/carers should be informed about the medical background of the newborn hearing screening programme and the screening test procedure, and have the right to refuse to have their child screened
Summary
Universal Newborn Hearing Screening (NHS), as defined in the Children’s Directive [1], has been part of the national programme for the screening of infants in Germany since 2009. The aim of this article is to present some legal, methodological, organizational, financial, structural and technical aspects of audiological measurement in newborns (screening), tracking and diagnosis in Germany. The information provided here is based on the standards and protocols specified in the Children’s Directive [1] and the consideration of structures that have been developed before and after the introduction of the NHS in Germany. The tracking of findings in need of further monitoring by hearing screening centres (tracking) and specialist medical follow-up (confirmation diagnostics) are presented in separate sections
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
